市場調査レポート

商品コード

1284116

ナノメディシンの世界市場の評価：ナノ分子タイプ別、用途別、適応症別、地域別、機会、予測（2016年～2030年）

Global Nanomedicine Market Assessment, By Nanomolecule Type, By Application, By Disease Indication, By Region, Opportunities, and Forecast 2016-2030F

出版日: 2023年06月01日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 105 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 707,130円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 895,698円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,288,548円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のナノメディシンの市場規模は、2022年の1,684億米ドルから2030年に3,197億2,000万米ドルに達し、2023年～2030年の予測期間にCAGRで8.34%の成長が予測されています。新しいドラッグデリバリー技術の出現や、多くの医療用途におけるナノメディシンの利点、政府による支援と融資の増加が、市場の拡大を促進しています。

当レポートでは、世界のナノメディシン市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

市場規模と予測
- 金額
- 数量
ナノ分子タイプ別
- ナノ粒子
- ナノシェル
- ナノデバイス
- ナノチューブ
用途別
- ドラッグデリバリー
- ワクチン
- 画像診断
- 再生医療
- その他
適応症別
- 腫瘍性疾患
- 感染症
- 整形外科疾患
- 心血管疾患
- その他
地域別
- 北米
- 欧州
- 南米
- アジア太平洋
- 中東・アフリカ
市場シェア：企業別（2022年）

第7章世界のナノメディシン市場の見通し：地域別（2016年～2030年）

北米
- ナノ分子タイプ別
- 用途別
- 適応症別
- 地域別
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- イタリア
- 英国
- デンマーク
- トルコ
- スペイン
南米
- ブラジル
- アルゼンチン
- コロンビア
アジア太平洋
- インド
- 中国
- 日本
- オーストラリア
- ベトナム
- 韓国
- マレーシア
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- 南アフリカ
- イスラエル
- クウェート

第8章市場マッピング（2022年）

ナノ分子タイプ別
用途別
適応症別
地域別

第9章マクロ環境と業界構造

需給の分析
輸出入の分析 - 数量と金額
サプライ/バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第10章市場力学

成長促進要因
成長抑制要因（課題と抑制要因）

第11章規制の枠組みとイノベーション

臨床試験
特許情勢
FDAの承認
イノベーション/新興技術

第12章主要企業情勢

マーケットリーダー上位5社の競合マトリックス
マーケットリーダー上位5社の市場収益分析（2022年）
合併と買収/合弁事業（該当する場合）
SWOT分析（市場参入企業5社向け）

第13章価格分析

第14章ケーススタディ

第15章主要企業の見通し

Pfizer Inc.
Sanofi S.A.
Amgen Inc
Moderna, Inc
Novo Nordisk A/S
Celgene Corporation
Teva
Pharmaceutical Industries Ltd.
Abbott Laboratories
Johnson & Johnson Services, Inc.
Merck & Co., Inc

第16章戦略的推奨事項

第17章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Types from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 2. Global Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 3. Global Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 4. Global Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 5. Global Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 6. Global Nanomedicine Market Share, By Region, In USD Billion, 2016-2030F
Figure 7. North America Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 8. North America Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 9. North America Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 10. North America Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 11. North America Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 12. North America Nanomedicine Market Share, By Country, In USD Billion, 2016-2030F
Figure 13. United States Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 14. United States Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 15. United States Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 16. United States Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 17. United States Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 18. Canada Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 19. Canada Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 20. Canada Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 21. Canada Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 22. Canada Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 23. Mexico Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 24. Mexico Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 25. Mexico Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 26. Mexico Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 27. Mexico Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 28. Europe Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 29. Europe Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 30. Europe Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 31. Europe Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 32. Europe Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 33. Europe Nanomedicine Market Share, By Country, In USD Billion, 2016-2030F
Figure 34. Germany Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 35. Germany Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 36. Germany Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 37. Germany Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 38. Germany Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 39. France Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 40. France Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 41. France Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 42. France Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 43. France Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 44. Italy Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 45. Italy Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 46. Italy Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 47. Italy Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 48. Italy Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 49. United Kingdom Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 50. United Kingdom Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 51. United Kingdom Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 52. United Kingdom Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 53. United Kingdom Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 54. Denmark Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 55. Denmark Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 56. Denmark Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 57. Denmark Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 58. Denmark Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 59. Turkey Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 60. Turkey Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 61. Turkey Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 62. Turkey Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 63. Turkey Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 64. Spain Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 65. Spain Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 66. Spain Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 67. Spain Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 68. Spain Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 69. South America Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 70. South America Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 71. South America Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 72. South America Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 73. South America Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 74. South America Nanomedicine Market Share, By Country, In USD Billion, 2016-2030F
Figure 75. Brazil Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 76. Brazil Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 77. Brazil Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 78. Brazil Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 79. Brazil Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 80. Argentina Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 81. Argentina Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 82. Argentina Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 83. Argentina Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 84. Argentina Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 85. Colombia Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 86. Colombia Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 87. Colombia Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 88. Colombia Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 89. Colombia Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 90. Asia-Pacific Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 91. Asia-Pacific Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 92. Asia-Pacific Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 93. Asia-Pacific Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 94. Asia-Pacific Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 95. Asia-Pacific Nanomedicine Market Share, By Country, In USD Billion, 2016-2030F
Figure 96. India Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 97. India Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 98. India Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 99. India Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 100. India Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 101. China Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 102. China Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 103. China Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 104. China Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 105. China Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 106. Japan Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 107. Japan Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 108. Japan Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 109. Japan Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 110. Japan Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 111. Australia Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 112. Australia Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 113. Australia Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 114. Australia Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 115. Australia Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 116. Vietnam Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 117. Vietnam Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 118. Vietnam Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 119. Vietnam Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 120. Vietnam Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 121. South Korea Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 122. South Korea Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 123. South Korea Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 124. South Korea Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 125. South Korea Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 126. Malaysia Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 127. Malaysia Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 128. Malaysia Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 129. Malaysia Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 130. Malaysia Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 131. Middle East & Africa Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 132. Middle East & Africa Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 133. Middle East & Africa Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 134. Middle East & Africa Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 135. Middle East & Africa Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 136. Middle East & Africa Nanomedicine Market Share, By Country, In USD Billion, 2016-2030F
Figure 137. Saudi Arabia Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 138. Saudi Arabia Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 139. Saudi Arabia Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 140. Saudi Arabia Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 141. Saudi Arabia Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 142. UAE Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 143. UAE Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 144. UAE Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 145. UAE Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 146. UAE Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 147. South Africa Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 148. South Africa Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 149. South Africa Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 150. South Africa Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 151. South Africa Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 152. Israel Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 153. Israel Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 154. Israel Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 155. Israel Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 156. Israel Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 157. Kuwait Nanomedicine Market, By Value, In USD Billion, 2016-2030F
Figure 158. Kuwait Nanomedicine Market, By Volume, In Tons, 2016-2030F
Figure 159. Kuwait Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
Figure 160. Kuwait Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
Figure 161. Kuwait Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
Figure 162. By Nanomolecule Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 163. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 164. By Disease Indication Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022

Product Code: MX10084

Global Nanomedicine Market size was valued at USD 168.4 billion in 2022 which is expected to reach USD 319.72 billion in 2030 growing with a CAGR of 8.34% for the forecast period between 2023 and 2030.

Emerging new drug delivery technologies, the benefits of nanomedicine in numerous healthcare applications, and an increase in government support and financing are driving market expansion. Furthermore, the growing need for safe and cost-effective medicines contributes to market expansion.

Nanomedicine enhances the delivery of medicine by manipulating materials at the nanoscale. Therefore, nanomedicine has made it possible to treat a variety of diseases. As several products are in the development stage, nanomedicine is now in its infancy. The developing technologies for drug delivery are important elements that are anticipated to boost the growth of the nanomedicine market in the forecast period. However, the industry is projected to be hampered by the lengthy clearance procedure and the complications associated with the use of nanomedicines.

Advancement in Medical Technology

The invention of nanoscale medication delivery devices has been one of the most significant advances in nanomedicine. These methods employ nanoparticles to deliver medications directly to specific cells or tissues in the body, lowering the risk of adverse effects and increasing therapy efficacy. These drug delivery systems have the potential to transform the treatment of numerous illnesses, including cancer, diabetes, and cardiovascular disease.

Nanosensor is another significant milestone in nanomedicine which can detect and measure particular molecules or biomarkers in the body, offering vital diagnostic information for a variety of disorders. Nanosensors offer the potential to enhance early identification and treatment of numerous diseases by monitoring anything from blood glucose levels in diabetic patients to cancer indicators in cancer patients.

Increasing Awareness of Nanomedicines Among General Population

The worldwide nanomedicine market is primarily driven by rising healthcare awareness. People are more inclined to seek out medical treatment and services as they grow more conscious of the value of their health and wellness. With increased awareness of the potential benefits of nanomedicine, there has been a substantial surge in research and development activity in this sector. This has resulted in the creation of various innovative nanomedicine products and therapies, which are propelling the industry forward. Furthermore, the frequency of chronic illnesses including cancer, diabetes, and cardiovascular disorders is rising, which has increased demand for nanomedicine. Nanomedicine has emerged as a promising alternative for the treatment of various disorders due to its capacity to target certain cells and tissues in the body.

Government Initiatives

Government agencies are probably going to enhance their R&D spending, creating appealing chances for market development. Massive capital-intensive projects can be accelerated with the help of government funding. To improve nanoscale engineering, science, and technology, the National Science Foundation announced that it will spend a total of USD 84 million over the course of five years to re-establish the National Nanotechnology Coordinated Infrastructure. Additionally, the Canadian government funds research in the fields of nanomedicine and regenerative medicine at the Canadian Institutes of Health Research (CIHR) and the Canadian Space Agency (CSA). As a result, it will fuel the expansion of the nanomedicine sector in the upcoming years.

Innovations in Nanomedicine

It is projected that the development of innovative nanoscience-based treatments will be actively pursued by reputable pharmaceutical firms, which will have an impact on the market for nanomedicine. For instance, in May 2022, the Marble Centre for Cancer Nanomedicine, in association with Alloy Therapeutics, FUJIFILM Holdings America Corporation, Sanofi, and Danaher Corporation, introduced an affiliate programme.

The programme intends to promote industry-academia research partnerships to support ground-breaking breakthroughs in the nanomedicine sector. Additionally, the expansion of the nanomedicine sector is anticipated to be aided by breakthroughs in nanotechnology and its growing applications in preventative interventions, early illness detection, prevention of chronic as well as acute diseases, and prophylaxis of acute as well as chronic disorders.

Impact of COVID-19

The global market for nanomedicine has been significantly impacted by the COVID-19 pandemic. While the pandemic brought difficulties for the sector, it also offered chances for development and innovation.

The pandemic impacted the nanomedicine supply chain by creating delays and shortages. The pandemic expedited nanomedicine research and development efforts, with many firms and researchers shifting their emphasis to finding answers to the virus. Nanomedicine has been at the forefront of COVID-19 therapy development, such as the utilisation of nanoparticles for medication delivery and the creation of nanosensors for viral detection.

Key Players Landscape and Outlook

According to a study article titled "Recent Advances in Nanomaterials Development for Nanomedicine and Cancer" that was published in July 2021, Point-of-care and extremely sensitive techniques of cancer diagnosis have also been developed using a lot of nano-based materials and technologies. As a result, the market is expanding due to developments in nanomedicine for the diagnosis of cancer.

In January 2022, Pfizer and Acuitas Therapeutics announced their agreement for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics.

Market Xcel's reports answer the following questions:

What is the current and future market size of the product/service in question globally or specific to different countries?

How are the markets divided into different product/service segments and the market size and growth of each segment?

What is the market potential of different product segments and their invest case?

How are the markets predicted to develop in the future and what factors will drive or inhibit growth?

What is the business environment and regulatory landscape specific to the product/service?

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19

4. Impact of Russia-Ukraine War

5. Executive Summary

6. Global Nanomedicine Market Outlook, 2016-2030F

6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.1.2. By Volume
6.2. By Nanomolecule Type
- 6.2.1. Nanoparticles
  - 6.2.1.1. Polymer-Based
  - 6.2.1.2. Lipid-Based
  - 6.2.1.3. Nanocrystals
  - 6.2.1.4. Inorganic
  - 6.2.1.5. Others
- 6.2.2. Nanoshells
- 6.2.3. Nanodevices
- 6.2.4. Nanotubes
6.3. By Applications
- 6.3.1. Drug Delivery
- 6.3.2. Vaccines
- 6.3.3. Diagnostic Imaging
- 6.3.4. Regenerative Medicine
- 6.3.5. Others
6.4. By Disease Indication
- 6.4.1. Oncological Diseases
- 6.4.2. Infectious Diseases
- 6.4.3. Orthopedic Disorders
- 6.4.4. Cardiovascular Diseases
- 6.4.5. Others
6.5. By Region
- 6.5.1. North America
- 6.5.2. Europe
- 6.5.3. South America
- 6.5.4. Asia-Pacific
- 6.5.5. Middle East & Africa
6.6. By Company Market Share (%), 2022

7. Global Nanomedicine Market Outlook, By Region, 2016-2030F

7.1. North America*
- 7.1.1. By Nanomolecule Type
  - 7.1.1.1.1. Nanoparticles
  - 7.1.1.1.1.1. Polymer-Based
  - 7.1.1.1.1.2. Lipid-Based
  - 7.1.1.1.1.3. Nanocrystals
  - 7.1.1.1.1.4. Inorganic
  - 7.1.1.1.1.5. Others
  - 7.1.1.1.2. Nanoshells
  - 7.1.1.1.3. Nanodevices
  - 7.1.1.1.4. Nanotubes
- 7.1.2. By Applications
  - 7.1.2.1.1. Drug Delivery
  - 7.1.2.1.2. Vaccines
  - 7.1.2.1.3. Diagnostic Imaging
  - 7.1.2.1.4. Regenerative Medicine
  - 7.1.2.1.5. Others
- 7.1.3. By Disease Indication
  - 7.1.3.1.1. Oncological Diseases
  - 7.1.3.1.2. Infectious Diseases
  - 7.1.3.1.3. Orthopedic Disorders
  - 7.1.3.1.4. Cardiovascular Diseases
  - 7.1.3.1.5. Others
- 7.1.4. By Region
  - 7.1.4.1.1. North America
  - 7.1.4.1.2. Europe
  - 7.1.4.1.3. South America
  - 7.1.4.1.4. Asia-Pacific
  - 7.1.4.1.5. Middle East & Africa
- 7.1.5. United States*
  - 7.1.5.1. By Nanomolecule Type
  - 7.1.5.1.1. Nanoparticles
  - 7.1.5.1.1.1. Polymer-Based
  - 7.1.5.1.1.2. Lipid-Based
  - 7.1.5.1.1.3. Nanocrystals
  - 7.1.5.1.1.4. Inorganic
  - 7.1.5.1.1.5. Others
  - 7.1.5.1.2. Nanoshells
  - 7.1.5.1.3. Nanodevices
  - 7.1.5.1.4. Nanotubes
  - 7.1.5.2. By Applications
  - 7.1.5.2.1. Drug Delivery
  - 7.1.5.2.2. Vaccines
  - 7.1.5.2.3. Diagnostic Imaging
  - 7.1.5.2.4. Regenerative Medicine
  - 7.1.5.2.5. Others
  - 7.1.5.3. By Disease Indication
  - 7.1.5.3.1. Oncological Diseases
  - 7.1.5.3.2. Infectious Diseases
  - 7.1.5.3.3. Orthopedic Disorders
  - 7.1.5.3.4. Cardiovascular Diseases
  - 7.1.5.3.5. Others
- 7.1.6. Canada
- 7.1.7. Mexico

All segments will be provided for all regions and countries covered

7.2. Europe
- 7.2.1. Germany
- 7.2.2. France
- 7.2.3. Italy
- 7.2.4. United Kingdom
- 7.2.5. Denmark
- 7.2.6. Turkey
- 7.2.7. Spain
7.3. South America
- 7.3.1. Brazil
- 7.3.2. Argentina
- 7.3.3. Colombia
7.4. Asia-Pacific
- 7.4.1. India
- 7.4.2. China
- 7.4.3. Japan
- 7.4.4. Australia
- 7.4.5. Vietnam
- 7.4.6. South Korea
- 7.4.7. Malaysia
7.5. Middle East & Africa
- 7.5.1. Saudi Arabia
- 7.5.2. UAE
- 7.5.3. South Africa
- 7.5.4. Israel
- 7.5.5. Kuwait

8. Market Mapping, 2022

8.1. By Nanomolecule Type
8.2. By Application
8.3. By Disease Indication
8.4. By Region

9. Macro Environment and Industry Structure

9.1. Supply Demand Analysis
9.2. Import Export Analysis - Volume and Value
9.3. Supply/Value Chain Analysis
9.4. PESTEL Analysis
- 9.4.1. Political Factors
- 9.4.2. Economic System
- 9.4.3. Social Implications
- 9.4.4. Technological Advancements
- 9.4.5. Environmental Impacts
- 9.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
9.5. Porter's Five Forces Analysis
- 9.5.1. Supplier Power
- 9.5.2. Buyer Power
- 9.5.3. Substitution Threat
- 9.5.4. Threat from New Entrant
- 9.5.5. Competitive Rivalry

10. Market Dynamics

10.1. Growth Drivers
10.2. Growth Inhibitors (Challenges, Restraints)

11. Regulatory Framework and Innovation

11.1. Clinical Trials
11.2. Patent Landscape
11.3. FDA Approvals
11.4. Innovations/Emerging Technologies

12. Key Players Landscape

12.1. Competition Matrix of Top Five Market Leaders
12.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
12.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
12.4. SWOT Analysis (For Five Market Players)

13. Pricing Analysis

14. Case Studies

15. Key Players Outlook

15.1. Pfizer Inc.
- 15.1.1. Company Details
- 15.1.2. Key Management Personnel
- 15.1.3. Products & Services
- 15.1.4. Financials (As reported)
- 15.1.5. Key Market Focus & Geographical Presence
- 15.1.6. Recent Developments
15.2. Sanofi S.A.
15.3. Amgen Inc
15.4. Moderna, Inc
15.5. Novo Nordisk A/S
15.6. Celgene Corporation
15.7. Teva
15.8. Pharmaceutical Industries Ltd.
15.9. Abbott Laboratories
15.10. Johnson & Johnson Services, Inc.
15.11. Merck & Co., Inc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

ナノメディシンの世界市場の評価：ナノ分子タイプ別、用途別、適応症別、地域別、機会、予測（2016年～2030年）

Global Nanomedicine Market Assessment, By Nanomolecule Type, By Application, By Disease Indication, By Region, Opportunities, and Forecast 2016-2030F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章 COVID-19の影響

第4章ロシア・ウクライナ戦争の影響

第5章エグゼクティブサマリー

第6章世界のナノメディシン市場の見通し（2016年～2030年）

第7章世界のナノメディシン市場の見通し：地域別（2016年～2030年）

第8章市場マッピング（2022年）

第9章マクロ環境と業界構造

第10章市場力学

第11章規制の枠組みとイノベーション

第12章主要企業情勢

第13章価格分析

第14章ケーススタディ

第15章主要企業の見通し

第16章戦略的推奨事項

第17章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19

4. Impact of Russia-Ukraine War

5. Executive Summary

6. Global Nanomedicine Market Outlook, 2016-2030F

7. Global Nanomedicine Market Outlook, By Region, 2016-2030F

8. Market Mapping, 2022

9. Macro Environment and Industry Structure

10. Market Dynamics

11. Regulatory Framework and Innovation

12. Key Players Landscape

13. Pricing Analysis

14. Case Studies

15. Key Players Outlook

16. Strategic Recommendations

17. About Us & Disclaimer

ナノメディシンの世界市場の評価：ナノ分子タイプ別、用途別、適応症別、地域別、機会、予測（2016年～2030年）

Global Nanomedicine Market Assessment, By Nanomolecule Type, By Application, By Disease Indication, By Region, Opportunities, and Forecast 2016-2030F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 COVID-19の影響

第4章 ロシア・ウクライナ戦争の影響

第5章 エグゼクティブサマリー

第6章 世界のナノメディシン市場の見通し（2016年～2030年）

第7章 世界のナノメディシン市場の見通し：地域別（2016年～2030年）

第8章 市場マッピング（2022年）

第9章 マクロ環境と業界構造

第10章 市場力学

第11章 規制の枠組みとイノベーション

第12章 主要企業情勢

第13章 価格分析

第14章 ケーススタディ

第15章 主要企業の見通し

第16章 戦略的推奨事項

第17章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19

4. Impact of Russia-Ukraine War

5. Executive Summary

6. Global Nanomedicine Market Outlook, 2016-2030F

7. Global Nanomedicine Market Outlook, By Region, 2016-2030F

8. Market Mapping, 2022

9. Macro Environment and Industry Structure

10. Market Dynamics

11. Regulatory Framework and Innovation

12. Key Players Landscape

13. Pricing Analysis

14. Case Studies

15. Key Players Outlook

16. Strategic Recommendations

17. About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第4章ロシア・ウクライナ戦争の影響

第5章エグゼクティブサマリー

第6章世界のナノメディシン市場の見通し（2016年～2030年）

第7章世界のナノメディシン市場の見通し：地域別（2016年～2030年）

第8章市場マッピング（2022年）

第9章マクロ環境と業界構造

第10章市場力学

第11章規制の枠組みとイノベーション

第12章主要企業情勢

第13章価格分析

第14章ケーススタディ

第15章主要企業の見通し

第16章戦略的推奨事項

第17章当社について・免責事項